A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking 'hundreds of millions' in damages
Lilly returns to Innovent to partner on cancer and immune diseases
Lilly returns to Innovent to partner on cancer and immune diseases
Hims says it will stop selling GLP-1 pill, after legal pressure from US
Hims says it will stop selling GLP-1 pill, after legal pressure from US
#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS
#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
US calls for DOJ investigation of Hims over GLP-1 drugs
US calls for DOJ investigation of Hims over GLP-1 drugs
TrumpRx launch falls flat for some, citing generic access
TrumpRx launch falls flat for some, citing generic access
HHS drops legal fight over blocked 340B rebate pilot
HHS drops legal fight over blocked 340B rebate pilot
Orphan drug tweak in US spending bill will make life easier for the FDA
Orphan drug tweak in US spending bill will make life easier for the FDA
Agomab, SpyGlass cap biggest week for biotech IPOs since 2021
Agomab, SpyGlass cap biggest week for biotech IPOs since 2021
Biogen CEO says Alzheimer's drug Leqembi on track for continued growth
Biogen CEO says Alzheimer's drug Leqembi on track for continued growth
UniQure pauses higher doses in Fabry study; Aro shares Pompe data
UniQure pauses higher doses in Fabry study; Aro shares Pompe data
Geoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at Daiichi
Geoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at Daiichi
Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis
Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis
Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown
Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown
Illumina bets on healthcare after Trump administration's NIH funding disruptions
Illumina bets on healthcare after Trump administration's NIH funding disruptions
FDA chief Makary takes aim at Hims' compounded Wegovy pill plans
FDA chief Makary takes aim at Hims' compounded Wegovy pill plans
Novo's threat to sue Hims over Wegovy pill faces legal hurdle
Novo's threat to sue Hims over Wegovy pill faces legal hurdle
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page